Publicacións nas que colabora con José Alcamí Pertejo (47)

2023

  1. Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern

    Journal of medical virology, Vol. 95, Núm. 3, pp. e28679

  2. Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

    Cancers, Vol. 15, Núm. 8

2022

  1. Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19

    Journal of Clinical Medicine, Vol. 11, Núm. 10

  2. Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection

    Journal of Clinical Medicine, Vol. 11, Núm. 8

  3. Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster

    Cancers, Vol. 14, Núm. 22

  4. Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection

    Frontiers in Cell and Developmental Biology, Vol. 10

2021

  1. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

    Journal of Clinical Investigation, Vol. 131, Núm. 20

  2. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission

    Journal of Clinical Medicine, Vol. 10, Núm. 1, pp. 1-21

  3. Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU

    Frontiers in Immunology, Vol. 12

  4. Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity

    Frontiers in Immunology, Vol. 12

  5. Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence

    Biochemical Pharmacology, Vol. 194

  6. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

    Biochemical Pharmacology, Vol. 192

2020

  1. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection

    Biochemical Pharmacology, Vol. 182

  2. Dasatinib protects humanized mice from acute HIV-1 infection

    Biochemical Pharmacology, Vol. 174

2019

  1. HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study

    Scientific Reports, Vol. 9, Núm. 1

  2. HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights

    AIDS Research and Human Retroviruses, Vol. 35, Núm. 7, pp. 598-607

  3. The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection

    PLoS Pathogens, Vol. 15, Núm. 8

  4. Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV

    Current HIV/AIDS Reports, Vol. 16, Núm. 5, pp. 414-422

2018

  1. Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 156, pp. 248-264

  2. Factors leading to the loss of natural elite control of HIV-1 infection

    Journal of Virology, Vol. 92, Núm. 5